Five-Year Survival Rate of Patients with End-Stage Renal Disease on Continuous Ambulatory Peritoneal Dialysis (CAPD) at Malang CAPD Center, Indonesia

Atma Gunawan, Pandu Tridana Sakti


Background: Continuous Ambulatory Peritoneal Dialysis (CAPD) is an alternative therapy for renal replacement in patients with kidney failure in developing countries such as Indonesia. The CAPD program in Malang Indonesia has been running since 2010. Until now, there has been little research on the mortality of CAPD therapy in Indonesia. We aimed to provide report on the characteristics and 5-year survival of CAPD therapy in patients with end-stage renal disease (ESRD) in developing countries like Indonesia. Methods: We conducted a retrospective cohort study involving 674 patients with end-stage renal disease receiving CAPD therapy from the medical records of the CAPD Center RSUD Dr. Saiful Anwar from August 2014 to July 2020. The 5-year survival rate was analyzed using Kaplan-Meier, and the hazard ratio was analyzed using Cox regression. Results: Of 674 patients with end-stage renal disease who underwent CAPD, 63.2% survived up to 5 years, with general survival rates at 1, 3, and 5 years of 80%, 60%, and 52%, respectively. The 3-year survival rate for patients with end-stage renal disease and comorbid hypertension was 80%, while it was 10% for patients with comorbid hypertension and type II diabetes mellitus. The hazard ratio for patients with end-stage renal disease who had comorbid hypertension and type II diabetes mellitus was 8.4 (95% CI = 6.36-11.21). Conclusion: Patients with end-stage renal disease who receive CAPD therapy have a favorable 5 years survival rate. Patients with end-stage renal disease on CAPD therapy who have comorbid hypertension and type II diabetes mellitus have a lower survival rate than patients with comorbid hypertension alone.


Survival; End Stage Kidney Disease; Continuous Ambulatory Peritoneal Dialysis


Li PK-T, Chow KM, Van de Luijtgaarden MWM, et al. Changes in the worldwide epidemiology of peritoneal dialysis. Nat Rev Nephrol. 2017;13(2):90–103.

Indonesia PN. 11th Report of Indonesian renal registry 2018. Jakarta Perhimpun Nefrol Indones. 2018

Witowski J, López-Cabrera M. Peritoneal dialysis and its local and systemic complications: From the bench to the clinic. Front Physiol. 2020;11:188.

Canney M, Er L, Antonsen J, Copland M, Singh RS, Levin A. Maintaining the uptake of peritoneal dialysis during the covid-19 pandemic: a research letter. Can J Kidney Heal Dis. 2021;8:2054358120986265.

Klomjit N, Kattah AG, Cheungpasitporn W. The cost-effectiveness of peritoneal dialysis is superior to hemodialysis: Updated evidence from a more precise model. Kidney Med. 2021;3(1):15.

Sukul N, Mukhopadhyay P, Schaubel DE, et al. Peritoneal dialysis and mortality, kidney transplant, and transition to hemodialysis: trends from 1996-2015 in the United States. Kidney Med. 2020;2(5):610–9.

Thurlow JS, Joshi M, Yan G, et al. Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy. Am J Nephrol. 2021;52(2):98–107.

Wouk N. End-stage renal disease: Medical management. Am Fam Physician. 2021;104(5):493–9.

Hansson JH, Finkelstein FO. Peritoneal dialysis in the United States: Lessons for the Future. Kidney Med. 2020;2(5):529.

Wu C, Chen X, Ying Wang A, et al. Peritoneal dialysis in Sichuan province of China–report from the Chinese National Renal Data System. Ren Fail. 2018;40(1):577–82.

Preka E, Bonthuis M, Harambat J, et al. Association between timing of dialysis initiation and clinical outcomes in the paediatric population: an ESPN/ERA-EDTA registry study. Nephrol Dial Transplant. 2019;34(11):1932–40.

Prasad B, Jafari M, Shah S, McNaught C, Diebel L. Barriers to peritoneal dialysis in Saskatchewan Canada: results from a province-wide survey. Can J kidney Heal Dis. 2020;7:2054358120975545.

Sianturi DA, Gunawan A. Peritonitis as the cause of death of CAPD patients at RSUD Dr. Saiful Anwar Malang 2014-2020. Clin Res J Intern Med. 2022;3(1):239–44.

McDonald SP. Australia and New Zealand dialysis and transplant registry. Kidney Int Suppl. 2015;5(1):39–44.

Toth-Manikowski S, Atta MG. Diabetic kidney disease: pathophysiology and therapeutic targets. J Diabetes Res. 2015;2015.

Full Text: PDF


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.